Library · Metabolic & weight · Treatment of obesity and type 2 diabetes
Retatrutide
GGG Tri-agonist, GLP-1/GIP/Glucagon receptor agonist, LY-3437943
A triple agonist (LY3437943) hitting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. Trial data show strong weight loss and glucose control, exceeding many dual agonists; it is in Phase 3 testing for obesity and type 2 diabetes.
Research score 90/100. Reference only, not a dose.
- Appetite Suppression
- Metabolic Enhancement
- Blood Sugar Control
- Weight Loss
- GLP-1 Agonist
- GIP Agonist
- US status
- Investigational
- Approval
- Phase 3 Clinical Trial
- Evidence
- Phase 3 trials ongoing (TRIUMPH program). Phase 2 data published in NEJM showing significant efficacy.
- Research score
- 90 / 100
- Indication
- Obesity/Weight Management
- Origin
- USA
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
GLP-1 activation drives glucose-dependent insulin release and satiety; GIP activation improves insulin sensitivity and nutrient storage; glucagon-receptor activation raises energy expenditure and fat metabolism, together producing added metabolic effect; structural changes allow once-weekly dosing.
Safety file
Profile similar to other incretin drugs; nausea and diarrhea are common and dose-related; a transient heart-rate increase has been observed.
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Gastrointestinal discomfort
- Injection site reactions